TENX

SEC Filing Summary: Synthetic Blood International, Inc. (10-K)

Business Context and Reporting Period

Company: Synthetic Blood International, Inc. (SBI)
Filing Type: Form 10-K (Annual Report)
Period Ended: April 30, 2001
Stage: Development-stage enterprise with no commercial revenue.
Core Business: SBI is developing three primary product candidates based on perfluorocarbon and biosensor technology: Oxycyte (synthetic blood substitute), Fluorovent (liquid ventilation for acute respiratory distress), and an implantable continuous glucose biosensor for diabetics. All products are in the preclinical stage, requiring FDA approval before clinical trials can commence.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Costs: Total expenses rose 116% to $2.0 million. Research and Development (R&D) expenses surged 249% to $782,339, driven by increased laboratory wages ($387k), rent ($87k), and supplies ($83k). General and Administrative (G&A) expenses increased 77% to $1.2 million due to higher consulting, market research, and investor relations costs.
• Improved Interest Income: Other income jumped to $331,019 from $16,141, primarily due to interest earned on significantly higher cash balances.
• Cash Position: Cash decreased by $1.2 million during the year, with $1.5 million used in operations and $317k in investing activities. This was partially offset by $640k in financing activities from stock sales.
• Debt Reduction: Interest expense dropped to $1,070 from $15,882 due to the reduction of outstanding notes payable. However, the company incurred a new $135,000 promissory note for laboratory equipment.

Outlook, Risks, and Management Commentary

• Liquidity: Management estimates existing cash ($4.25 million) will fund operations for approximately two years (through late 2003). Substantial additional financing is required to begin and complete clinical trials.
• Strategy: The company intends to minimize fixed expenses and partner with pharmaceutical/medical device companies for funding and commercialization. No partnership agreements are currently in place.
• Risk Factors:
  • Development Risk: All products are preclinical; there is no assurance of FDA approval or commercial success.
  • Capital Risk: Failure to secure additional financing could force the company to curtail or cease operations.
  • Profitability: The company expects to incur substantial losses for the foreseeable future.
  • Competition: Intense competition exists in blood substitutes, liquid ventilation, and glucose monitoring, with many competitors further along in clinical trials.
• Unusual Items: The company cancelled a $600,000 stock subscription receivable and related 4.5 million shares due to non-payment. Significant stock issuances occurred for services rendered and to satisfy prior deposits.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "2-year" cash runway estimate given the accelerating burn rate in R&D.
• Capital Needs: Assess the specific capital requirements to move from preclinical to Phase I clinical trials, as no commitments for future funding exist.
• Partnership Status: Confirm if any progress has been made in securing the strategic partnerships deemed essential for commercialization.
• Dilution Risk: Review the impact of the 4.1 million outstanding stock options and potential future equity raises on shareholder value.
• Regulatory Path: Evaluate the timeline and costs associated with FDA IND (Investigational New Drug) applications for Oxycyte, Fluorovent, and the biosensor.